Sanofi has entered into a strategic manufacturing collaboration with Boehringer Ingelheim for the manufacture of therapeutic monoclonal antibodies (mAbs).
Sanofi has entered into a strategic manufacturing collaboration with Boehringer Ingelheim for the manufacture of therapeutic monoclonal antibodies (mAbs). This move reinforces manufacturing capacity to support upcoming product launches.
Sanofi reported in a press release that biologics make up 72% of its R&D projects, half of which are mAbs.
Advertisement
Under the terms of the agreement, Sanofi will have access to Boehringer Ingelheim’s capabilities in Biberach an der Riss, Germany to transfer and manufacture therapeutic mAbs. Product transfers is expected to commence in early 2015 according to Sanofi. No financial terms were disclosed.
